Toronto Western Hospital - University Health Network
Welcome,         Profile    Billing    Logout  
 5 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pereira, Vitor Mendes
NCT06165341: Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

Recruiting
3
50
Europe, Canada, US
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo
Takeda
Alpha1-Antitrypsin Deficiency
08/28
08/28
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting
3
160
Europe, Canada, US, RoW
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride
Takeda, Takeda Development Center Americas, Inc.
Alpha1-Antitrypsin Deficiency
03/27
03/29
EVOLVE, NCT04195568: Evaluation of Safety and Effectiveness of Stryker Surpass Evolve™ Flow Diverter System

Active, not recruiting
N/A
248
Canada, US, RoW
Surpass Evolve Flow Diverter System
Stryker Neurovascular
Aneurysm, Intracranial
12/24
09/28
NCT06761365: LUMENS-1 EU EFS CIP

Recruiting
N/A
30
Europe
LuSeed Aneurysm Embolization System
LuSeed Vascular LTD.
Aneurysm Cerebral, Bifurcation, Unruptured Intracranial Aneurysm, Saccular Aneurysm, Brain Aneurysm
12/26
06/27
Rosenblat, Joshua D
NCT05029466: Psilocybin for Treatment-Resistant Depression

Completed
2
30
Canada
Psilocybin
Brain and Cognition Discovery Foundation, Braxia Scientific Corp., Usona Institute
Treatment Resistant Depression
07/23
07/23
PSI-1V2, NCT06341426: Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin

Recruiting
2
92
Canada
Single Psychedelic Dose Psilocybin, Two Psychedelic Doses Psilocybin
University Health Network, Toronto, Centre for Addiction and Mental Health
Major Depressive Disorder, Depression, Treatment-Resistant Depression, Mood Disorders
02/28
08/28
KET-BD, NCT05004896: Ketamine for Treatment-Resistant Bipolar Disorder

Recruiting
2
100
Canada
Ketamine Hydrochloride, Midazolam Hydrochloride
Joshua Rosenblat
Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
04/25
12/25
KET-BD-Sustain, NCT05339074: Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression

Recruiting
2
60
Canada
Ketamine Hydrochloride
Joshua Rosenblat
Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
08/25
02/26
Psilo-BD, NCT06506019: Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression

Recruiting
1
30
Canada
Psilocybin, Functional MRI
University Health Network, Toronto, Centre for Addiction and Mental Health
Bipolar Depression
09/26
01/27
ENABLE, NCT06408012: An Innovative Master Platform for Clinical Trials in Mood Disorders

Recruiting
N/A
900
Canada
St. Joseph's Healthcare Hamilton, Unity Health Toronto, Centre for Addiction and Mental Health, Queen's University, University of Ottawa, University of British Columbia, University of Calgary, McGill University, Nova Scotia Health Authority, University of Michigan, Simon Fraser University, University Health Network, Toronto
Mood Disorders, Depressive Disorder, Bipolar and Related Disorders
03/26
03/26
Kaczmarek, Erica
Psilo-BD, NCT06506019: Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression

Recruiting
1
30
Canada
Psilocybin, Functional MRI
University Health Network, Toronto, Centre for Addiction and Mental Health
Bipolar Depression
09/26
01/27

Download Options